...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of diagnostic pathology >Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome
【24h】

Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome

机译：从皮肤淋巴易瘤和霉菌菌和SEZARY综合征的皮肤淋巴易瘤和SEZARY综合征的疾病演化中抑制信号受体编程死亡标记-1（PD-1）的上调

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background Negative immunoregulatory checkpoints impede effective immune responses to tumor and reduce the action of anticancer agents. One such example is programmed death marker-1 (PD-1), an inhibitory signaling receptor expressed on activated and regulatory T-cells. PD-1 expression was reported in a few reports, but the expression profile of PD-1 and mycosis fungoides (MF) remains largely to be characterized. Design In this study, skin biopsies from 42 prelymphomatous T-cell dyscrasias (CLD), 9 Sezary's syndrome (SS), 103 MF, and 20 CD30 + lymphoproliferative diseases (LPD) were examined for PD-1 expression using immunohistochemistry. Results PD-1 staining was observed amidst many neoplastic T-cells in 6/9(66.7%) and 62/103 (60.2%) cases of SS and MF respectively, while only 6/42 (14.3%) cases of CLD and 0/20 (0%) cases of CD30 + LPD ( P 0.001). Three cases are from same patients representing different stages of disease evolution from CLD to MF and SS with a corresponding enrichment of PD-1 positivity. In all cases there was variable staining of PD-1 amidst macrophages. There was no correlation with disease progression among MF cases. Twenty cases of CD30 + LPD did not show any PD-1 positivity. Conclusion PD-1 seems to correlate with disease progression in epitheliotropic T cell dyscrasias ranging from minimal staining in prelymphomatous dyscrasias to significant staining in MF, likely reflecting the effects of PD-1 on inhibiting tumor surveillance regulatory T cell populations. PD-1 was consistently expressed in MF while it was consistently negative in primary CD30 + LPD, suggesting the possibility of using PD-1 as a means of distinguishing CD30 + MF from primary cutaneous ALCL. Highlights ? Largest case studies examining PD-1 of 112 samples of Mycosis fungoides and Sezary’s syndrome. ? PD-1 seems to correlate with disease progression in epitheliotropic T cell dyscrasias. ? PD-1 staining in CD30 positive lymphomatoid papulosis and anaplastic large cell lymphoma is rarely reported, and is negative in this study.
机译：摘要背景负免疫调节检查点妨碍肿瘤的有效免疫应答，减少抗癌剂的作用。一个这样的例子是编程死亡标记-1（PD-1），抑制信号传导受体在活性和调节性T细胞上表达。在几个报告中报道了PD-1表达，但PD-1和肌菌菌诱导（MF）的表达谱重数在很大程度上是特征。本研究中的设计，使用免疫组织化学检查PD-1表达，检查来自42只Prelymphomatous T细胞缺陷（CLD），9 sezary的综合征（SS），103mF和20d30 +淋巴抑制性疾病（LPD）的皮肤活组织检查。结果在6/9（66.7％）和SS和MF的62/103（60.2％）分别的许多肿瘤T细胞中观察到PD-1染色，而SS和MF的62/103例，而CLD的6/42（14.3％） / 20（0％）CD30 + LPD的病例（P <0.001）。三种病例来自代表从CLD到MF和SS的不同疾病演化阶段的患者，其具有相应的PD-1阳性的富集。在所有情况下，在巨噬细胞中有Pd-1的可变染色。 MF病例中没有与疾病进展相关的相关性。二十例CD30 + LPD没有显示任何PD-1阳性。结论PD-1似乎与上皮细胞疾病中的疾病进展相关，从植物粘性多种染色中的最小染色到MF中的显着染色，可能反映了PD-1对抑制肿瘤监测调控性T细胞群的影响。 PD-1在MF中始终表达，而在原发性CD30 + LPD中始终是阴性，表明使用PD-1作为区分CD30 + MF与初级皮肤ALCL的方法的可能性。强调 ？最大的案例研究检查了112个肌瘤诱导物和Sezary综合征的PD-1。还PD-1似乎与上皮细胞缺陷中的疾病进展相关。还PD-1在CD30阳性淋巴瘤肿瘤和芳香族大细胞淋巴瘤中染色很少报道，并且在本研究中是否定的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号